ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 21:54:40 | |||
| 787 USD | +3.19% |
|
787.2 | +0.03% |
| 04:49pm | UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | RE |
| 02:43pm | Eli Lilly Ethics/Compliance Chief Alonzo Weems to Retire | DJ |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.29% | 36 M€ | +3.82% | - | |
| 0.27% | 1 M€ | -.--% | - | |
| 0.24% | 12 M€ | +14.87% | - | |
| 0.23% | 17 M€ | +5.10% | - | |
| 0.22% | 105 M€ | +4.05% | - | |
| 0.21% | 7 M€ | +6.84% | - | |
| 0.21% | 32 M€ | +2.15% | - | |
| 0.21% | 17 M€ | +6.84% | - | |
| 0.20% | 253 M€ | +7.47% | ||
| 0.19% | 17 M€ | +2.74% | - | |
| 0.18% | 20 M€ | +1.40% | - | |
| 0.17% | 32 M€ | +1.38% | - | |
| 0.15% | 2 M€ | +5.96% | - | |
| 0.15% | 234 M€ | +7.45% | - | |
| 0.11% | 2 M€ | +3.16% | - | |
| 0.11% | 23 M€ | +14.19% | - | |
| 0.11% | 54 M€ | +1.07% | - | |
| 0.10% | 756 M€ | +1.40% | - | |
| 0.09% | 8 M€ | +0.48% | - | |
| 0.08% | 6 M€ | -4.26% | - | |
| 0.08% | 3 M€ | +6.30% | - | |
| 0.02% | 104 M€ | +10.67% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.01% | 688B | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
